NewAmsterdam Pharma Co N.V. (NAMS): Cash & Equivalents
$490.00M
As of 2025-12-31
$424.15M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $490.00M | -36.5% | 2026-02-18, Balance as of period end |
| 2024-12-31 | $771.74M | +126.7% | 2026-02-18, Balance as of period end |
| 2023-12-31 | $340.45M | n/a | 2026-02-18, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $5.63M | -58.2% |
| Scynexis Inc (SCYX) | 2025-12-31 | $21.26M | +32.4% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $578.0K | -22.0% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $90.39M | -10.7% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $11.03M | -43.4% |
| Celularity Inc (CELU) | 2025-12-31 | $6.17M | +736.7% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $27.14M | +20.8% |
Compare NAMS, ALMS, CASIF, SCYX side by side · Screen every company in Pharmaceutical Preparations ↗